Šenolt et al. [22] proved that treatment with etanercept, a TNF-α inhibitor, is associated with an increase in leptin expression and lowering of adiponectin levels in the subcutaneous adipose tissue of subjects with RA, and Renzo et al. [23] observed, in psoriasis vulgaris and psoriatic arthritis patients treated with TNF-α inhibitors, an 8.6% and an 8.9% gain in fat mass, respectively. Here, LEP is linked to psoriatic arthritis.